BioCubaFarma

Havana, Dec 27 (RHC) The Business Group of the Biotechnological and Pharmaceutical Industries of Cuba (Biocubafarma) will celebrate today its tenth anniversary as a culmination of the successful linkage of science, production, and commercialization of medicines.

Biocubafarma was officially created on December 7, 2012, from the integration of the entities belonging to the Scientific Pole and the Quimefa Business Group, for the manufacture of medicines, equipment, and high-tech services.

Such products aim to improve human health, generate exportable goods and services, and produce food with advanced technologies.

With more than 21,600 workers, hundreds of highly professional specialists integrated into research production, and 62 production facilities, it represents a strategic industry, with high standards for its products and services and a solid international positioning.

It is currently made up of 45 companies with 110 production lines, and 391 investment projects and has 21 science and technology units associated, organized under the principle of a closed-cycle company that integrates all the stages of production, from research to commercialization.

Biocubafarma manufactures 525 drugs out of the 849 that make up the basic list of medicines of the Cuban Ministry of Public Health, and has 802 health records abroad, in addition to exporting its products to 48 countries.

Its important contributions are added to the fight and treatment of cancer, complications of diabetes, autoimmune diseases, and infectious diseases, as part of its research programs.

Its main results include Heberprot P for diabetic foot ulcers, Nimotuzumab for head and neck cancer, and the vaccine against rotavirus and pneumococcus.

Representative of his work was assuming in a few months the creation of safe and effective vaccines against Covid-19, caused by SARS-Cov-2, as well as the manufacture in a record time of the necessary doses for mass immunization, including those of reinforcement, which was crucial to control the disease.

From the work of its researchers and technical personnel, Soberana 02, Soberana Plus, and Abdala emerged, with which it is possible to exhibit a high level of vaccination, hence Cuba has a complete immunization schedule for 10 million three thousand 464 people, the 90.3 percent of the population. (Source: PL).